{"title":"Faricimab for treating wet AMD and diabetic macular oedema","authors":"S. Chaplin","doi":"10.1002/psb.2026","DOIUrl":null,"url":null,"abstract":"Faricimab (Vabysmo) is a bispecific antibody against angiopoietin‐2 and VEGF‐A for the treatment of adults with wet age‐related macular degeneration (AMD) and visual impairment due to diabetic macular oedema. This article discusses its administration, clinical trial outcomes and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Faricimab (Vabysmo) is a bispecific antibody against angiopoietin‐2 and VEGF‐A for the treatment of adults with wet age‐related macular degeneration (AMD) and visual impairment due to diabetic macular oedema. This article discusses its administration, clinical trial outcomes and place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
